Study on Noom Program's Impact on GLP-1 Medication Users
This study evaluates the Noom program's effectiveness for patients on GLP-1 medications, which could validate digital health interventions in diabetes management. Successful outcomes may prompt pharma companies to adjust their portfolios to include or partner with digital lifestyle programs as adjunct therapies.
Phase III
Centers for Disease Control and Prevention
Status
Active
Sponsor
Noom
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
This study evaluates the Noom program's effectiveness for patients on GLP-1 medications, which could validate digital health interventions in diabetes management. Successful outcomes may prompt pharma companies to adjust their portfolios to include or partner with digital lifestyle programs as adjunct therapies.
Why it matters
This study evaluates the Noom program's effectiveness for patients on GLP-1 medications, which could validate digital health interventions in diabetes management. Successful outcomes may prompt pharma companies to adjust their portfolios to include or partner with digital lifestyle programs as adjunct therapies.
What changed
Trial Update
Analysis
The study evaluates the effectiveness of the Noom digital lifestyle program for adults on GLP-1 medications.
This study evaluates the Noom program's effectiveness for patients on GLP-1 medications, which could validate digital health interventions in diabetes management. Successful outcomes may prompt pharma companies to adjust their portfolios to include or partner with digital lifestyle programs as adjunct therapies.
Monitor outcomes related to behavioral changes and health improvements among participants, as well as implementation metrics.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.